Targeting the glucocorticoid receptor as a therapeutic strategy for ovarian cancer: The ROSELLA study

Q: How does OCRA curate its research paper database?

OCRA indexes peer-reviewed papers from PubMed and CrossRef, enriched with MeSH terms, author profiles, and citation metrics. Papers are categorized by cancer type, research method, and clinical relevance.

Q: Can I search papers by MeSH term or author?

Yes. Use the search bar to filter papers by MeSH term, author name, journal, keyword, or cancer type. Each paper includes linked MeSH terms and author profiles for further exploration.

Q: How current is the paper database?

The database is updated regularly through automated ingestion from PubMed and CrossRef. Most papers appear within days of their PubMed indexing date.

doi:10.1016/j.medj.2025.100848

Targeting the glucocorticoid receptor as a therapeutic strategy for ovarian cancer: The ROSELLA study

Taliya Lantsman & Ursula A. Matulonis

The ROSELLA trial tested the combination of intermittently dosed relacorilant, a novel glucocorticoid receptor antagonist, plus nab-paclitaxel versus nab-paclitaxel alone in recurrent platinum-resistant ovarian cancer (PROC).

Links

DOI PubMed

Journal

Med

Authors

Taliya Lantsman, Ursula A. Matulonis

Funding

Foundation for Women's Cancer Funding Breast Cancer Research Foundation Funding Developmental Funds Combined ATR and P13k inhibition in uterine cancer

National Cancer Institute

P30CA006516

National Cancer Institute

P01CA269021